Accueil>>Signaling Pathways>> PROTAC>>AT6

AT6

Catalog No.GC33354

AT6 est un analogue PROTAC AT1, qui est un PROTAC connecté par des ligands pour von Hippel-Lindau et BRD4 avec une haute sélectivité au bromodomaine (Brd4).

Products are for research use only. Not for human use. We do not sell to patients.

AT6 Chemical Structure

Cas No.: 2098836-50-9

Taille Prix Stock Qté
1mg
270,00 $US
En stock
5mg
585,00 $US
En stock
10mg
945,00 $US
En stock
25mg
1 935,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

AT6 is a PROTAC AT1 analogue, which is a highly selective bromodomain (Brd4) degrader.

PROTACs (proteolysis-targeting chimaeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase: PROTAC: target species and how this impacts target degradation selectivity remains elusive. The ligand folds into itself to allow formation of specific intermolecular interactions in the ternary complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and proximity assays, are consistent with pronounced cooperative formation of ternary complexes with Brd4BD2. Structure-based-designed compound AT1 exhibits highly selective depletion of Brd4 in cells[1].

[1]. Gadd MS, et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat Chem Biol. 2017 May;13(5):514-521.

Avis

Review for AT6

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AT6

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.